| 摘要 |
<p>A hypolipidaemic drug may be administered in combination with therapeutically active composition comprising at least one omega-3 polyunsaturated fatty acid (PUFA) in the same oral dosage form by having medicated print containing the hypolipidaemic drug on the outer surface of the oral dosage form which contains the therapeutically active composition. Advantages include not only reducing the number of oral dosage forms to be taken by a patient thereby increasing patient compliance and reducing the risk of under-medication, but also providing a simple and effective way of separating chemically and/or physically incompatible therapeutic compounds within the same oral dosage form.</p> |
